CytomX Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from CytomX Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $-1,564 of operating cash. Lower than almost all Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 43% in 3 years; of every extra $100 of sales, $356 became extra profit. Higher than 91% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$-1,564Over the last 3 years, every $100 of reported profit came with $-1,564 of operating cash.
Lower than almost all Healthcare companies in United States.
Self-Funding Ratio
-159.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 87% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$356Sales grew 43% in 3 years; of every extra $100 of sales, $356 became extra profit.
Higher than 91% of Healthcare companies in United States.
Asset Productivity Ratio
+43% / -42%In 3 years sales changed by +43% while total assets changed by -42%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-17.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 52% of Healthcare companies in United States.
Cash Cushion Ratio
+25%Cash, after subtracting all debt, equals 25% of its market value (net cash).
Higher than 66% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 89% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 90% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
CytomX Therapeutics, Inc. made a loss over the last year. CytomX Therapeutics, Inc. owes $0.21 for every $1 it owns. CytomX Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCytomX Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.76The share price is 1.76 times CytomX Therapeutics, Inc.'s book value per share, lower than 63% of Healthcare companies in United States.
Market cap
$532 MThe total market value of all of CytomX Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 55% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$302 MWhat CytomX Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.39Net worth divided by the number of shares. The share price of $2.44 is 1.8 times this, which is the P/B above.
Return on equity (ROE)
-37.8%CytomX Therapeutics, Inc. lost 37.8% of its shareholders' money over the last year, higher than 56% of Healthcare companies in United States.
Owes vs Owns
0.21×CytomX Therapeutics, Inc. owes $0.21 for every $1 it owns (low), lower than 71% of Healthcare companies in United States.
Dividend yield
NoneCytomX Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-45%Revenue fell 45% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Profit growth
LossCytomX Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-22.8%CytomX Therapeutics, Inc. lost $23 for every $100 of revenue.
Cash vs debt
Net cashCytomX Therapeutics, Inc. held $133 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For CytomX Therapeutics, Inc.: $532 M ÷ $302 M (30 Jun 2026) = 1.8.
What is CytomX Therapeutics, Inc.'s return on equity?
CytomX Therapeutics, Inc. lost 37.8% of its shareholders' money over the last year, higher than 56% of Healthcare companies in United States.
How much does CytomX Therapeutics, Inc. owe compared with what it owns?
CytomX Therapeutics, Inc. owes $0.21 for every $1 it owns (low), lower than 71% of Healthcare companies in United States.
Does CytomX Therapeutics, Inc. pay a dividend?
No. CytomX Therapeutics, Inc. does not currently pay a dividend.
Is CytomX Therapeutics, Inc.'s revenue growing?
Revenue fell 45% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.